TREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA
Journal of Ayub Medical College Abbottabad · 2024
DOI: 10.55519/jamc-02-12695 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ayub Medical College Abbottabad, 2024. Verfasst von Muhammad Farooq Latif und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dubai Hospital, Dubai-UAE. Hauptthemen laut MEDLINE: Gestational Trophoblastic Disease, Methotrexate, Antineoplastic Combined Chemotherapy Protocols, Chorionic Gonadotropin. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Background
This research aims to assess the treatment outcomes and chemotherapy duration required for the normalization of Human chorionic gonadotropin (HCG) levels in patients diagnosed with Gestational Trophoblastic Neoplasia (GTN), encompassing both benign and malignant forms of the condition.
Methods
This retrospective study included GTD patients treated with chemotherapy in a single oncology clinic from January 2016 to May 2022. Clinical data were gathered from electronic records of the patients.
Results
During the study period, a total of 24 patients diagnosed with GTD underwent chemotherapy, with a median age of 32 years (range: 18–51). Intramuscular Methotrexate was the primary single-agent chemotherapy utilized in 20 cases (83%) for low-risk disease, while the EMA-CO regimen was the predominant combination chemotherapy employed in 3 cases (13%) for high-risk disease. The median number of chemotherapy cycles administered was 2 (range: 1–16), with a median duration of 4 weeks (range: 1–16) required for Human chorionic gonadotropin (HCG) normalization. Approximately half of the patients (n=10, 47.5%) transitioned to second-line combination chemotherapy, with a median normalization duration of 4 months. Four patients (40%) subsequently received third-line combination chemotherapy using the EMA-CO regimen. Initial complete response was achieved in 11 patients (47%) with first-line treatment, while 10 patients (43%) required second-line chemotherapy and 4 patients (17%) necessitated third-line EMACO chemotherapy. Of the 24 patients, 22 achieved complete response, while 2 patients are currently undergoing treatment.
Conclusion
All patients successfully attained complete response with chemotherapy. The median duration of chemotherapy for achieving normalization of HCG was 4 weeks, equivalent to 2 cycles. Notably, only 4 patients necessitated third-line chemotherapy following single-agent chemotherapy in the first and second lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dubai Hospital, Dubai-UAE.
- Department of Medical Oncology, King Fahad Specialist Hospital, Dammam-Saudi Arabia.
- Department of Medical Oncology, Prince Sultan Military Medical City, Riyadh-Saudi Arabia.
Zitieren
APA
Latif, M. F., Azam, F., Hassan Tirmazy, S. H., & Bukhari, N. (2024). TREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA. Journal of Ayub Medical College Abbottabad. https://doi.org/10.55519/jamc-02-12695
Vancouver
Latif MF, Azam F, Hassan Tirmazy SH, Bukhari N. TREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA. Journal of Ayub Medical College Abbottabad. 2024. doi:10.55519/jamc-02-12695
BibTeX
@article{Latif2024,
author = {Latif, Muhammad Farooq and Azam, Faisal and Hassan Tirmazy, Syed Hammad and Bukhari, Nedal},
title = {TREATMENT OUTCOMES OF GESTATIONAL TROPHOBLASTIC DISEASE, EXPERIENCE FROM SAUDI ARABIA},
journal = {Journal of Ayub Medical College Abbottabad},
year = {2024},
doi = {10.55519/jamc-02-12695}
}
EUVIMED